|
CYTK | Cytokinetics Inc |
| Pharmaceutical Preparations |
| Book value per $ invested | $ -0.11 |
| Leverage | 146.30% |
| Market Cap | $ 6.1B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -782.6m |
| Margin | -574.69% |
Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is headquartered in South San Francisco, California.